The landscape of germline mutations and the relationship with tumor mutation burden in Chinese patients with lung cancer.

Authors

null

Jian Shi

Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Jian Shi , Rongfeng Liu , Guanglei Huang , Lixing Wang , Baoen Shan , Ningning Luo , Qin Zhang , Didi Guo , Yaqing Wu , Yingxue Qi

Organizations

Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Department of Research Center, Fourth Hospital of Hebei Medical University, Shjiazhuang, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China

Research Funding

No funding received
None

Background: Lung cancer is one of the most common types of cancer, ranking the first in the incidence and mortality of malignant tumors in the world and China. Although studies have been reported that genetic susceptibility to lung cancer is associated with certain germline mutations, the relationship between lung cancer risk and inherited genetic factors remains relatively elusive. However, the effect of germline mutation on TMB in lung cancer has not been explored. Herein, DNA genomic profiling was performed through NGS with a 539-gene panel to explore the germline mutations and the relationship with TMB in Chinese patients with lung cancer. Methods: We retrospectively analyzed the germline mutations through a comprehensive 539-gene profiling of 3541 Chinese patients with lung cancer. 539-gene panel contained germline mutations in 90 hereditary tumor-associated genes. We screened out the pathogenic and likely pathogenic germline mutations according to the standards and guidelines for the interpretation of sequence variants of The American College of Medical Genetics and Genomics (ACMG), and picked out there is no records in Clinvar database and no literature report. TMB of tissue or blood ctDNA in 3541 patients were further analyzed in with pathogenic mutations (P group), with likely pathogenic mutations (LP group), and no germline mutations group (Non-P group). The difference in TMB was analyzed via the Wilcoxon sign test. Results: In 3541 patients with lung cancer, 177 (4.999%) patients were identified harboring pathogenic or likely pathogenic germline mutations, in which 78 P group and 99 LP group, the rest 3364 were Non-P group. The highest prevalence of germline mutation was found in BRCA2 (0.565%), ATM (0.339%), MUTYH (0.282%), and BRCA1 (0.254%). In 177 patients with pathogenic or likely pathogenic germline mutations, 67 mutations were recorded as UNK (unknow) in Clinvar database and no literature report. The media TMB of tissue in P group, LP group and Non-P group were 5.149, 5.535 and 5.547 respectively. The media TMB of blood ctDNA in P group, LP group and Non-P group were 4.257, 3.945 and 4.483 respectively. There was no statistical difference in TMB between P and Non-P groups (tissue p = 0.98; ctDNA p = 0.5). Conclusions: In our study, we firstly identified 67 novel germline mutations and studied on the relationship between germline mutations and TMB in lung cancer, which expanded the understanding of germline mutations.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Cancer Genetics

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 10522)

DOI

10.1200/JCO.2021.39.15_suppl.10522

Abstract #

10522

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Genitourinary Cancers Symposium

Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in BRCA2.

First Author: Minqi Huang

Abstract

2021 Genitourinary Cancers Symposium

ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.

First Author: Ellen Jaeger

Abstract

2020 ASCO Virtual Scientific Program

The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.

First Author: Lele Song

Abstract

2022 ASCO Annual Meeting

Lung cancer patients with germline mutations have a unique fusion molecular spectrum.

First Author: Zixin Yang